Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14647439 | 0.84 | BTK (0.47) | BTKTNK2TLR7SRCABL1 | |
| SCHEMBL14637033 | 0.77 | BTK (0.36) | BTKTNK2SRC | |
| SCHEMBL23111989 | 0.77 | TNK2 (0.51) | BTKTNK2TLR7SRCABL1 | |
| SCHEMBL23044547 | 0.74 | BTK (0.48) | BTKTNK2SRCABL1 | |
| SCHEMBL3540179 | 0.74 | NUDT1 (0.36) | BTKTNK2TLR7SRCABL1 | |
| SCHEMBL31391151 | 0.72 | ABL1 (0.43) | BTKTNK2SRCABL1 | |
| SCHEMBL1129368 | 0.71 | NUDT1 (0.34) | BTKTNK2SRCABL1 | |
| SCHEMBL18099733 | 0.71 | ABL1 (0.53) | BTKTNK2TLR7SRCABL1 | |
| SCHEMBL31330632 | 0.71 | TNK2 (0.51) | BTKTNK2TLR7SRCABL1 | |
| SCHEMBL31330580 | 0.71 | TNK2 (0.40) | BTKTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734529-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2548877-A1 | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors | MSD Oss B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008899-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | BTK 1/4885TNK2 203/4885TLR7 916/4885 |
| US-20140221333-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | BTK 1/4885TNK2 188/4885TLR7 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.